RAVEL-TECHNOLOGIES
23.8.2022 19:28:16 CEST | Business Wire | Press release
Ravel Technologies S.A.S. (“Ravel'' or “Company”) proudly unveils several major patent-pending breakthroughs in Fully Homomorphic Encryption (FHE). Now 4 orders of magnitude faster than state-of-the-art, Ravel’s algorithmic discoveries are designed to make FHE finally scalable. The team is now building a sophisticated suite of fully encrypted technologies including the first fully encrypted SQL database equipped to query billions of encrypted data points, as well as advanced machine learning algorithms.
“Now that we have successfully overcome FHE’s biggest challenges, we will begin to put its uniquely powerful, protective capabilities to work,” explains Ravel CEO Mehdi Sabeg. “We have identified exciting opportunities in financial markets and privacy-preserving personalised advertising. We plan to address a full spectrum of vertically-diverse use cases, such as health data management, supply chain, financial services, and public services utilising our data sharing and analytics platform.”
Ravel includes a team of outstanding senior researchers in mathematics and is advised by Fields Medal Recipient Cedric Villani.
“Given the impressive, major algorithmic breakthroughs achieved by Ravel’s team, Ravel Fully Homomorphic Encryption (RHE) is orders of magnitude faster than state-of-the-art FHE schemes,” notes Villani. “With the continual increase of personal and industrial data being processed globally, privacy, and confidentiality protection are of paramount importance. Ravel’s breakthroughs bring an efficient and scalable answer to critical data privacy and security challenges.”
Ravel’s ability to process encrypted data with low latency and high throughput provides unparalleled de-identification capabilities that can also facilitate targeted advertisements with zero-knowledge of the consumer. Brands worldwide have long sought after exactly this solution, one that doesn’t infringe on the privacy of their users.
In the same fashion, Ravel can operate fully encrypted financial exchanges and remove certain market biases induced by plaintext data that can be exploited in the bidding process, for example. In this sector, confidentiality protection becomes increasingly important for large financial institutions starting to rely on transparent blockchain infrastructure.
“As we experienced during our Proof of Concept, Ravel has demonstrated that its technology can enable secure and efficient processing for high volumes of encrypted data,” BNP Paribas Group Chief Information Officer and Executive Committee Member Bernard Gavgani confirms. “They are well on their way to solving data sharing and analytics challenges in banking and finance for brands worldwide. We look forward to pursuing our collaboration.”
As Ravel strengthens its technological edge, the team is focused on scaling up its commercial growth, with a concentration on building out its presence across the US and European markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005745/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
